Evidence map›Paper›PMID 32576885›Full record

ArticleScientific reports2020

Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer.

Andrew Dhawan, Jacob Scott, Purnima Sundaresan, Michael Veness, Sandro Porceddu, Eric Hau, Adrian L Harris, Francesca M Buffa, Harriet E Gee

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Observational
  3. Personalization of Radiotherapy Dose in HPV Positive Oropharynx Cancer Using GARD.medRxiv : the preprint server for health sciences · 2025
    Article
  4. Article
  5. Review
  6. Oncogenic Viruses as Entropic Drivers of Cancer Evolution.Frontiers in virology (Lausanne, Switzerland) · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Andrew DhawanDepartment of Oncology, University of Oxford, Oxford, United Kingdom. adhawan@qmed.ca.ORCID http://orcid.org/0000-0002-5027-1277
Jacob ScottTranslational Hematology and Oncology Research, Cleveland Clinic, Cleveland, Ohio, USA.ORCID http://orcid.org/0000-0003-2971-7673
Purnima SundaresanCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
Michael VenessCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
Sandro PorcedduPrincess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Eric HauCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
Adrian L HarrisDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0003-1376-8409
Francesca M BuffaDepartment of Oncology, University of Oxford, Oxford, United Kingdom.
Harriet E GeeCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia. Harriet.Gee@health.nsw.gov.au.
The University of Sydney · AUUniversity of Oxford · GBCleveland Clinic · USThe University of Queensland · AU

Funding

Cancer Research UK 23969
6 · The paper itself

Abstract

Treatment personalisation remains an unmet need in oropharynx cancer (OPC). We aimed to determine whether gene expression signatures improved upon clinico-pathological predictors of outcome in OPC. The clinico-pathological predictors, AJCC version 7 (AJCC 7), AJCC 8, and a clinical algorithm, were assessed in 4 public series of OPC (n = 235). Literature review identified 16 mRNA gene expression signatures of radiosensitivity, HPV status, tumour hypoxia, and microsatellite instability. We quality tested signatures using a novel sigQC methodology, and added signatures to clinico-pathological variables as predictors of survival, in univariate and multivariate analyses. AJCC 7 Stage was not predictive of recurrence-free survival (RFS) or overall survival (OS). AJCC 8 significantly predicted RFS and OS. Gene signature quality was highly variable. Among HPV-positive cases, signatures for radiosensitivity, hypoxia, and microsatellite instability revealed significant underlying inter-tumour biological heterogeneity, but did not show prognostic significance when adjusted for clinical covariates. Surprisingly, among HPV-negative cases, a gene signature for HPV status was predictive of survival, even after adjustment for clinical covariates. Across the whole series, several gene signatures representing HPV and microsatellite instability remained significant in multivariate analysis. However, quality control and independent validation remain to be performed to add prognostic information above recently improved clinico-pathological variables.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesGene Expression ProfilingHumansMaleMiddle AgedOropharyngeal NeoplasmsPrognosisRetrospective StudiesBiomarkers, Tumor

Identifiers

PMID32576885
PMCPMC7311543
OpenAlexW3036183998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.